For those that follow the debate, back in the beginning of
this year numerous provinces delisted oxycodone and severely decrease its
access. The debate at the time was the
consequence of poorly prepared drug policy shifts on the large number of
prescription drug addicted persons. Oxycodone
loosing public funding DrPHealth Feb 22, 2012. Many of the predictions have materialized.
In the subsequent months numerous stories ran that followed
the impacts including the rise in heroin use Calgary
Sun article and the substantive costs associated with single oxycodone
doses for persons wishing to maintain their addictions. Limited value in managing the addiction has
been documented but is a potential positive outcome.
Now, in the weirdest of ironic moves. The very government that started the domino
of confusion and angst, has its left hand approving the generic form of
oxycodone.
Remember that one of the key switches that occurred was the
maker of OxyCotin restructured the formulation in a harm reduction effort by
utilizing slow release drug delivery mechanisms.
So the basic dilemma we have a drug that has been
demonstrated as unsafe but has not been delicensed totally by Health Canada. Because
it is not delisted, and the patent is expiring, Health Canada apparently does
not have the power to preclude the licensing of the generic formulations.
It is not bureaucracy run amok – but a symptom of a system
that was designed to preclude bureaucratic obstacles in the drug approval
process. That Minister Aglukkaq would stand up and say that politicians can’t
stop the process is an oxymoron – it is the politicians that set the process up
so it would not be stoppable.
As Andre Picard flags in his Globe and Mail piece, the
oxycodone situation is unique and requires political leadership Andre
Picard on oxycodone. Regrettably, this
federal government has consistently failed to show leadership on health issues –
and this is another example of its causing a problem that the provinces will be
expected to solve, and have to foot the bill for the associated costs.
No comments:
Post a Comment